Your browser doesn't support javascript.
loading
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
Aggarwal, Rahul; Bryce, Alan; Ryan, Charles J; Harzstark, Andrea; Derleth, Christina; Kim, Won; Friedlander, Terence; Lin, Amy M; Rodvelt-Bagchi, Tammy; Dhawan, Mallika; Zhang, Li; Lee, Mina; Siebeneck, Eric; Hough, Jeffrey; Small, Eric J.
Afiliação
  • Aggarwal R; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Rahul.Aggarwal@ucsf.edu.
  • Bryce A; Mayo Scottsdale Cancer Center, Scottsdale, AZ.
  • Ryan CJ; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Harzstark A; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Derleth C; Department of Medicine, Vanderbilt University, Nashville, TN.
  • Kim W; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Friedlander T; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Lin AM; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Rodvelt-Bagchi T; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Dhawan M; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Zhang L; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Lee M; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Siebeneck E; Mayo Scottsdale Cancer Center, Scottsdale, AZ.
  • Hough J; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Small EJ; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Urol Oncol ; 35(4): 149.e7-149.e13, 2017 04.
Article em En | MEDLINE | ID: mdl-28161323
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article